Official company source
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.
Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. News release, 2026-05-21.
Eli Lilly and CompanyPublished 2026-05-21Accessed 2026-07-12
Registry record
Source metadata
- Publisher
- Eli Lilly and Company
- Source type
- Official company source
- Registry ID
research-reta-04- Source code
- RETA-04
Source usage
Linked from 9 pages
Compound
Retatrutide
Video auditUnapproved Weight-Loss Drug 'Reta' Sold Online Despite Safety Concerns
Video auditRetatrutide Masterclass: How To Use It Optimally (Dose, Frequency, Diet, Exercise, & Supplements)
Video auditDr. Explains Why Retatrutide is KING of Fat Loss Peptides
Video auditSafety Concerns Over Doctors Prescribing an Experimental Weight-Loss Drug
Video auditNew Data Released on Weight-Loss Drug Retatrutide
ComparisonRetatrutide vs Tirzepatide
Evidence curationBest Peptides for Weight Loss
GuidePeptide Category Explainers: How Every Compound Class on This Site Is Defined
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.